ArticleJournal of medical case reports2025
Ross syndrome following COVID-19 infection in an 18-year-old Syrian male patient: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoss syndrome is an exceptionally rare disorder characterized by tonic pupils, areflexia, and anhidrosis, with a prevalence that appears to be higher in women than in men, typically presenting in individuals during their 30s. While Adie Syndrome closely mimics Ross syndrome, Adie syndrome lacks anhidrosis, making Ross syndrome clinically differentiable. This condition can manifest with a variety of symptoms, including cardiovascular anomalies attributable to autonomic nervous system dysfunction. We present the first case in the literature of COVID-19 being a potential trigger for Ross syndrome. CASE PRESENTATION: An 18-year-old Syrian male was evaluated at the ophthalmology clinic owing to progressive bilateral pupillary dilation following a symptomatic COVID-19 infection. Subsequent investigations and a thorough neurological examination revealed tonic pupils and areflexia, leading to an initial diagnosis of Adie syndrome. However, the patient's clinical picture expanded to include diffuse anhidrosis, prompting a revised diagnosis of Ross syndrome (refer to graphical abstract).
conclusionClinicians should remain vigilant regarding the possibility of undefined neurological or ophthalmic sequelae, including Adie syndrome and Ross syndrome, following COVID-19 infection, regardless of the severity of initial symptoms. Further research is warranted to elucidate the underlying mechanisms and to develop appropriate management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.